Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...

The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...

Add Yahoo as a preferred source to see more of our stories on Google. Few agents define SoC for first-line DLBCL Treatment of refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) has ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...